Michael Saitakis: immunotherapy and fibrotic disease

LinkedIn caption
🔬 Michael Saitakis at the ARDD 2026 poster session.
In his official abstract, Saitakis describes an immunotherapy project that starts with human data and tissue validation to identify potential targets while considering effects on healthy tissue. Idiopathic pulmonary fibrosis is the initial focus, with antibody-based approaches still being developed and tested.
The poster conversations put the research process in view: examining the evidence, explaining the choices behind a project, and considering what comes next. A closer look at the people working across aging biology and therapeutic development.
📷 Donis Perkins and Alex Zhavoronkov
#ARDD2026 #AgingResearch #DrugDiscovery
X caption
🔬 Michael Saitakis at the #ARDD2026 poster session. His official abstract describes an immunotherapy pipeline targeting senescent cells in fibrotic disease, starting with human data and tissue validation.
📷 Donis Perkins and Alex Zhavoronkov
Photo: Donis Perkins and Alex Zhavoronkov
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.